.......
So that wasn't what I said at all.
Novartis broke the population into subgroups and managed to show significance in certain preselected subgroups.
This is easier to do when the initial population is 4000 people, harder when it's 500.
Also referenced their previous studies showing similar results.
Does that make a bit more sense? if not I can't really help tbh.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-260
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.020(2.02%) |
Mkt cap ! $1.158B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $1.221M | 1.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 72840 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 73993 | 13 |
View Market Depth
| Last trade - 11.42am 15/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |